Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHQNVR)

Drug Name

YH001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	DTT	CTLA4	4.684	5.333	3.954	2.293

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Aggressive cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	DTT	CTLA4	2.73E-01	0.02	0.05

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04699929) A Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability,Efficacy and Pharmacokinetics of YH001 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Biocytogen